Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

Next Previous
X
Search
Trial Profile

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan

    • Most Recent Events

    • 30 Aug 2023 According to AbbVie media release, post-hoc analysis data (from two phase 3 studies NCT02261467 and NCT02261493) presented in the Journal of Cosmetic Dermatology.
    • 30 Aug 2023 Results of post hoc analysis (from two phase 3 studies NCT02261467 and NCT02261493) presented in the AbbVie Media Release
    • 18 Dec 2017 Accoridng to a Allergan media release, based on the data of this and other phase III trial (250239), Vistabel (botulinum toxin type A) received a positive opinion from ANSM (France) for the temporary treatment of moderate to severe forehead lines in adult patients in 30 European countries.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top